Jump to content

Seribantumab: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
create
 
m Added link to corresponding ligand page on the IUPHAR/BPS Guide to PHARMACOLOGY
Line 27: Line 27:
| ATC_suffix =
| ATC_suffix =
| PubChem =
| PubChem =
| IUPHAR_ligand = 8297
| DrugBank =
| DrugBank =
| C = 6340 | H = 9810 | N = 1690 | O = 1986 | S = 52
| C = 6340 | H = 9810 | N = 1690 | O = 1986 | S = 52

Revision as of 08:45, 2 July 2015

Seribantumab
Monoclonal antibody
Type?
SourceHuman
TargetHER3
Clinical data
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
Chemical and physical data
FormulaC6340H9810N1690O1986S52
Molar mass143.2 kDa g·mol−1

Seribantumab[1] is a monoclonal antibody designed for the treatment of cancer.[2]

This drug was developed by Sanofi/Merrimack Pharmaceuticals, Inc.

References

  1. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108" (PDF). WHO Drug Information. 26 (4).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Seribantumab, American Medical Association.